IMP Labeling Workflows That Reduce Relabeling Risk and Start-Up Delays
Investigational medicinal product (IMP) labeling sits at the heart of clinical trial supply, impacting departments across pharmaceutical organizations, from clinical operations and regulatory affairs to quality assurance and beyond. When labeling activities are managed across multiple systems, vendors and stakeholders, teams often face avoidable rework, conflicting label text versions, delayed translations, unclear approval pathways and change control gaps that can delay site activation or trigger costly relabeling.
This webinar will share firsthand experiences in centralizing the IMP labeling workflow to create a single, controlled pathway from label content creation through translation, regulatory alignment, artwork, proofing, print, release and distribution. The featured speakers will outline practical operating models that improve visibility and accountability. These include defining a “single source of truth” for label text, standardizing templates and phrasing libraries, establishing clear review and approval roles and building timelines that account for country-specific requirements.
Attendees will learn how centralized workflows can reduce cycle times while strengthening compliance, particularly for multilingual labeling, updates driven by amendments and global studies with staggered country start-ups. Real-world pitfalls and proven controls will also be covered, including versioning rules, translation handoffs, audit-ready documentation and KPI tracking to help prevent last-minute firefighting.
Register for this webinar to learn how labeling workflows can reduce IMP errors, strengthen compliance and support faster study start-up.
